Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 22c; Offers FY23 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. META
3. ANT
4. SPY
5. CART
6. XNCR
7. AZN
8. GMAB
9. FFAI
10. TSLA

Go back to Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 22c; Offers FY23 Revenue Guidance

Castle Biosciences Reports Second Quarter 2023 Results

August 2, 2023 4:05 PM EDT

Q2 2023 revenue increased 44% over Q2 2022 to $50 million

Q2 2023 total test reports increased 52% over Q2 2022

Raising full year 2023 revenue guidance to at least $180 million from $170-180 million

Conference call and webcast today at 4:30 p.m. ET

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2023.

Castle delivered an outstanding second quarter, with... More